|

Iruplinalkib tablets Clinical Trials

1 actively recruiting trial

▼ -1 trial since June 2026

Also known as: Qi Xin Ke

Top Sponsors

  • Peking University Shenzhen Hospital1

Indications

  • Lorlatinib1
  • Iruplinalkib1
  • ALK1
  • Real World Study1
  • Observational Study1

Other1 trial

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.